The Histology, Cell and Atheroma Core will provide five main services for investigators within the program project. 1) Tissue Processing and Immuno- and Histological Analysis, 2) Photo-documentation, image analysis and quantification and statistical testing of endpoint data for significance, 3) Mouse Lipidomic Analysis, 4) Primary endothelial cell isolation training and quality control for purity and 5) Isolation and culturing of bone marrow-derived macrophage training and reagents. The core has abundant experience and will coordinate with co-director, Dr. Jonathan Smith, Cleveland Clinic, on the detailed and quantitative analysis of atheroma lesions and murine lipidomics needed for these studies. Advanced histological processing and immunohistochemistry will be available to all projects. A key issue in the program goals has been the utilization of primary cell populations, primarily endothelial and bone marrow derived macrophage. Since different labs and individuals are currently isolating primary cells with variable levels of efficiency and application of quality control assessment of population purity, we have incorporated primary cell isolation and analysis into the core. The support from the core will allow investigators to develop projects and experiments without having technical difficulties with quantitative or cell isolation and analysis protocols is an integral component of the program project, provides expanded opportunities and goals for each project and will continue to be an indispensible resource for future efforts.
The Core Facility is necessary to support development of the individual projects. The application of specific techniques and models in a uniform manner will improve the interpretation of results, cross interpretation between projects and provide the most relevant information regarding the mechanisms of atherosclerosis and inflammatory events in vascular disease.
|Harel, Miriam; Ferrer, Fernando A; Shapiro, Linda H et al. (2016) Future directions in risk stratification and therapy for advanced pediatric genitourinary rhabdomyosarcoma. Urol Oncol 34:103-15|
|Gerber, Claire; Harel, Miriam; Lynch, Miranda L et al. (2016) Proximal tubule proteins are significantly elevated in bladder urine of patients with ureteropelvic junction obstruction and may represent novel biomarkers: A pilot study. J Pediatr Urol 12:120.e1-7|
|Blaho, Victoria A; Galvani, Sylvain; Engelbrecht, Eric et al. (2015) HDL-bound sphingosine-1-phosphate restrains lymphopoiesis and neuroinflammation. Nature 523:342-6|
|Ghosh, Mallika; Subramani, Jaganathan; Rahman, M Mamunur et al. (2015) CD13 restricts TLR4 endocytic signal transduction in inflammation. J Immunol 194:4466-76|
|Galvani, Sylvain; Sanson, Marie; Blaho, Victoria A et al. (2015) HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation. Sci Signal 8:ra79|
|Rahman, M Mamunur; Ghosh, Mallika; Subramani, Jaganathan et al. (2014) CD13 regulates anchorage and differentiation of the skeletal muscle satellite stem cell population in ischemic injury. Stem Cells 32:1564-77|
|Ghosh, Mallika; Gerber, Claire; Rahman, M Mamunur et al. (2014) Molecular mechanisms regulating CD13-mediated adhesion. Immunology 142:636-47|
|Blaho, Victoria A; Hla, Timothy (2014) An update on the biology of sphingosine 1-phosphate receptors. J Lipid Res 55:1596-608|
|Zhang, Yong; Tang, Wenwen; Zhang, Haifeng et al. (2013) A network of interactions enables CCM3 and STK24 to coordinate UNC13D-driven vesicle exocytosis in neutrophils. Dev Cell 27:215-26|
|Pereira, Flavia E; Cronin, Chunxia; Ghosh, Mallika et al. (2013) CD13 is essential for inflammatory trafficking and infarct healing following permanent coronary artery occlusion in mice. Cardiovasc Res 100:74-83|
Showing the most recent 10 out of 89 publications